Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry

Breast

Volumn 21, Issue 1, 2012, Pages 50-57

  Park, Seho ^a,b   Koo, Ja Seung ^a,b   Kim, Min Suk ^b,c   Park, Hyung Seok ^a   Lee, Jun Sang ^a   Lee, Jong Seok ^a   Kim, Seung Il ^a,b   Park, Byeong Woo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Target Molecule Study Group   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

Author keywords

Biomarker; Breast cancer; Immunohistochemistry; Molecular subtype; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT CANCER; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; VISCERAL METASTASIS;

EID: 84856358910     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.07.008     Document Type: Article

References (31)

1. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009, 20:628-635.
2. Perou C.M., Sorlie T., Eisen M.B., van de Rijin M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
3. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
4. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
5. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
6. Tang P., Skinner K.A., Hicks D.G. Molecular classification of breast carcinomas byimmunohistochemical analysis: are we ready?. Diagn Mol Pathol 2009, 18:125-132.
7. Rakha E.A., Reis-Filho J.S., Ellis I.O. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010, 120:293-308.
8. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
9. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatl Cancer Inst 2009, 101:736-750.
10. Goldhirsch A., Glick J.H., Gelber R.D., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. JNatl Cancer Inst 1998, 90:1601-1608.
11. Carlson R.W., Anderson B.O., Bensinger W., Cox C.E., Davidson N.E., Edge S.B., et al. NCCN practice guidelines for breast cancer. Oncol (Williston Park) 2000, 14:33-49.
12. Treatment of early-stage breast cancer. JAMA 1991, 265:391-395. NIH Consensus Conference.
13. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134:e48-e72.
14. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JClin Oncol 2007, 25:118-145.
15. Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B., Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006, 37:1217-1226.
16. Onitilo A.A., Engel J.M., Greenlee R.T., Mukesh B.N. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7:4-13.
17. Zhao J., Liu H., Wang M., Gu L., Guo X., Gu F., et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. JSurg Oncol 2009, 100:89-94.
18. Ihemelandu C.U., Naab T.J., Mezghebe H.M., Makambi K.H., Siram S.M., Leffall L.D., et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008, 247:463-469.
19. Bhargava R., Dabbs D.J. Luminal B breast tumors are not HER2 positive. Breast Cancer Res 2008, 10:404. author reply 5.
20. Wiechmann L., Sampson M., Stempel M., Jacks L.M., Patil S.M., King T., et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 2009, 16:2705-2710.
21. Crabb S.J., Cheang M.C., Leung S., Immonen T., Nielsen T.O., Huntsman D.D., et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 2008, 8:249-256.
22. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. JClin Oncol 2010, 28:1684-1691.
23. Lin Y., Yin W., Yan T., Zhou L., Di G., Wu J., et al. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer 2009, 9:342.
24. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. JClin Oncol 2010.
25. Dent R., Hanna W.M., Trudeau M., Rawlinson E., Sun P., Narod S.A. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009, 115:423-428.
26. Rodriguez-Pinilla S.M., Sarrio D., Honrado E., Hardisson D., Calero F., Benitez J., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006, 12:1533-1539.
27. Khatcheressian J.L., Wolff A.C., Smith T.J., Grunfeld E., Muss H.B., Vogel V.G., et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. JClin Oncol 2006, 24:5091-5097.
28. Di Cosimo S., Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. Nat Rev Clin Oncol 2010, 7:139-147. [corrected].
29. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. JClin Oncol 1996, 14:2738-2746.
30. Zaha D.C., Lazar E., Lazureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol 2010, 51:85-89.
31. de Ronde J., Wessels L., Wesseling J. Molecular subtyping of breast cancer: ready to use?. Lancet Oncol 2010, 11:306-307.